Showing 20 of 206 recruiting trials for “t-cell-prolymphocytic-leukemia”
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
👨⚕️ Seth E. Karol, MD, MSCI, St. Jude Children's Research Hospital📍 3 sites📅 Started Dec 2024View details ↗
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
👨⚕️ Seth E. Karol, MD, St. Jude Children's Research Hospital📍 3 sites📅 Started Dec 2024View details ↗
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
👨⚕️ Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center📍 7 sites📅 Started Nov 2024View details ↗
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
👨⚕️ Kerry A Rogers, MD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Nov 2024View details ↗
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
🏥 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started Oct 2024View details ↗
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL
👨⚕️ He Huang, MD, First Affiliated Hospital of Zhejiang University📍 1 site📅 Started Oct 2024View details ↗
Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Virtual Reality During Lumbar Punctures in Acute Lymphoblastic Leukemia
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
RecruitingNCT06508684 ↗
Current Status of BTKi Treatment for CLL/SLL in China
🏥 The First Affiliated Hospital with Nanjing Medical University📍 1 site📅 Started Jul 2024View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →